News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
698,478 Results
Type
Article (41506)
Company Profile (460)
Press Release (656512)
Section
Business (208347)
Career Advice (1999)
Deals (35935)
Drug Delivery (91)
Drug Development (83263)
Employer Resources (169)
FDA (16323)
Job Trends (15037)
News (351995)
Policy (32972)
Tag
Academia (2619)
Alliances (50557)
Alzheimer's disease (1257)
Approvals (16234)
Artificial intelligence (123)
Bankruptcy (361)
Best Places to Work (11656)
Biotechnology (345)
Breast cancer (105)
Cancer (917)
Career advice (1669)
Cell therapy (207)
Clinical research (65641)
Collaboration (336)
Compensation (159)
COVID-19 (2580)
Cystic fibrosis (82)
Data (848)
Diabetes (132)
Diagnostics (6149)
Drug pricing (83)
Earnings (85317)
Employer resources (147)
Events (112189)
Executive appointments (244)
FDA (16759)
Funding (300)
Gene therapy (161)
GLP-1 (589)
Government (4401)
Healthcare (18974)
Infectious disease (2653)
Inflammatory bowel disease (107)
Interviews (308)
IPO (16539)
Job creations (3693)
Job search strategy (1427)
Layoffs (434)
Legal (7922)
Lung cancer (158)
Manufacturing (152)
Medical device (13288)
Medtech (13293)
Mergers & acquisitions (19392)
Metabolic disorders (371)
Neuroscience (1508)
NextGen Class of 2024 (6727)
Non-profit (4530)
Northern California (1194)
Obesity (222)
Opinion (194)
Patents (95)
People (57459)
Pharmaceutical (86)
Phase I (20544)
Phase II (28964)
Phase III (21455)
Pipeline (205)
Postmarket research (2590)
Preclinical (8811)
Radiopharmaceuticals (250)
Rare diseases (192)
Real estate (5996)
Regulatory (21863)
Research institute (2402)
Resumes & cover letters (351)
Southern California (1083)
Startups (3745)
United States (11821)
Vaccines (550)
Weight loss (171)
Date
Last 7 days (795)
Last 30 days (2746)
Last 365 days (36627)
2024 (31052)
2023 (41013)
2022 (52276)
2021 (56765)
2020 (54924)
2019 (47419)
2018 (35697)
2017 (33025)
2016 (32346)
2015 (38396)
2014 (32185)
2013 (27109)
2012 (29220)
2011 (29863)
2010 (27992)
Location
Africa (731)
Arizona (194)
Asia (38390)
Australia (6379)
California (2756)
Canada (1170)
China (210)
Colorado (118)
Connecticut (126)
Europe (83666)
Florida (388)
Georgia (98)
Illinois (318)
Indiana (178)
Kansas (98)
Maryland (520)
Massachusetts (2279)
Michigan (144)
Minnesota (252)
New Jersey (821)
New York (840)
North Carolina (714)
Northern California (1194)
Ohio (124)
Pennsylvania (744)
South America (1105)
Southern California (1083)
Texas (386)
Washington State (329)
698,478 Results for "mabwell therapeutics inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Mabwell Announces Clinical Trial Progress of 9MW2821 in Triple-Negative Breast Cancer
Mabwell (688062.SH), an innovation-driven biopharmaceutical company with entire industry chain, announced the progress of the clinical study of its novel Nectin-4-targeting ADC (R&D code: 9MW2821) for triple-negative breast cancer.
May 13, 2024
·
6 min read
Mabwell Presented IDDC™ Platform Technology and ADC Drug Development Achievements at the 14th World ADC London
Mabwell, an innovation-driven biopharmaceutical company with entire industry chain, published “Mtoxin™ Payload Applied in IDDC™ ADC Platform Significant Increases Therapeutic Index and Overcome MultiDrug Resistance in Various Tumor” as poster presentation from March 12 to 15, 2024 at the 14th World ADC London.
March 21, 2024
·
6 min read
Mabwell Announces 9MW2821 Clinical Data and Latest Progress to be presented at 2024 ASCO Annual Meeting
Mabwell, an innovation-driven biopharmaceutical company, announced the data and latest progress of the Phase I/II clinical study of 9MW2821, a novel Nectin-4-targeting ADC for multiple advanced solid tumors, which will be reported as an oral presentation at the 2024 American Society of Clinical Oncology Annual Meeting.
May 24, 2024
·
7 min read
Drug Development
Mabwell Releases Preclinical Study Results of Multiple Innovative Drugs Released at the 2024 AACR Annual Meeting
Mabwell presented the preclinical research findings of three potential novel drug candidates in poster format at the American Association for Cancer Research (AACR) Annual Meeting, held from April 5 to 10, 2024.
April 16, 2024
·
7 min read
Drug Development
Our Mission at Voyager Therapeutics: Define the Future of Neurogenetic Medicines
We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system
May 8, 2024
·
2 min read
·
Voyager Therapeutics, Inc.
Mabwell to Present Pre-clinical Results at the 2024 American Association for Cancer Research (AACR) Annual Meeting
Mabwell announced that it will present results of three preclinical studies as poster presentation at the AACR Annual Meeting to be held in San Diego, from April 5-10, 2024.
March 12, 2024
·
7 min read
2024 ASCO | Mabwell to Present Clinical Data of 9MW2821 in Multiple Advanced Solid Tumor
Mabwell announced that the Phase I/II clinical study results of the novel Nectin-4-targeting ADC 9MW2821 for multiple advanced solid tumors will be presented in an oral presentation at the American Society of Clinical Oncology annual meeting, which will be held in Chicago, USA, from May 31-June 4, 2024.
April 25, 2024
·
5 min read
Mabwell to attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase
Mabwell, an innovative biopharmaceutical company with entire industry chain, announced that Dr. Hai Wu, R&D VP of Mabwell, will attend 42nd JP Morgan Healthcare Conference and present at Biotech Showcase in San Francisco, United States.
January 2, 2024
·
5 min read
SGO 2024 | The First Published Clinical Data of Nectin-4-Targeting ADC Developed by Mabwell in Cervical Cancer Demonstrates Its Outstanding Therapeutic Potential
Mabwell (688062.SH), an innovative-driven biopharmaceutical company with entire industry chain, presented the clinical study data of the 9MW2821 for patients with cervical cancer as focused plenary oral presentation at the Society of Gynecologic Oncology (SGO) annual meeting on March 16, 2024.
March 19, 2024
·
8 min read
Drug Development
Mabwell Publishes the Phase III Study Results on Its Denosumab Biosimilar (MW032) in the journal JAMA Oncology
Mabwell recently published the phase III study results of denosumab biosimilar (MW032) online in the international top journal of JAMA Oncology.
February 21, 2024
·
5 min read
1 of 69,848
Next
